Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

L. Kappos; A. Bar-Or; B.A.C. Cree; R.J. Fox; C. Giovannoni; P. Vermersch; D.L. Arnold; S. Arnould; T. Schertz; C. Wolf; E. Walstrom; F. Dahlke; L. H. Visser

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

L. Kappos, A. Bar-Or, B.A.C. Cree, R.J. Fox, C. Giovannoni, P. Vermersch, D.L. Arnold, S. Arnould, T. Schertz, C. Wolf, E. Walstrom, F. Dahlke, L. H. Visser

Onderzoeksoutput: Article › Academic › peer review

Originele taal-2	American English
Pagina's (van-tot)	1263-1273
Aantal pagina's	11
Tijdschrift	The Lancet (London)
Volume	391
Status	Published - 1 jan. 2018

Citeer dit

@article{f518a54cc5814268be8649b5e109383f,

title = "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study",

author = "L. Kappos and A. Bar-Or and B.A.C. Cree and R.J. Fox and C. Giovannoni and P. Vermersch and D.L. Arnold and S. Arnould and T. Schertz and C. Wolf and E. Walstrom and F. Dahlke and Visser, {L. H.}",

year = "2018",

month = jan,

day = "1",

language = "American English",

volume = "391",

pages = "1263--1273",

journal = "The Lancet (London)",

issn = "0140-6736",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

AU - Kappos, L.

AU - Bar-Or, A.

AU - Cree, B.A.C.

AU - Fox, R.J.

AU - Giovannoni, C.

AU - Vermersch, P.

AU - Arnold, D.L.

AU - Arnould, S.

AU - Schertz, T.

AU - Wolf, C.

AU - Walstrom, E.

AU - Dahlke, F.

AU - Visser, L. H.

PY - 2018/1/1

Y1 - 2018/1/1

M3 - Article

SN - 0140-6736

VL - 391

SP - 1263

EP - 1273

JO - The Lancet (London)

JF - The Lancet (London)

ER -